Opinion in Switzerland

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Abbey National/Credit Suisse: bailing out insurance

The day after the UK's FSA moved to reassure investors about the safety of the life and pensions sector, two more life insurers were forced to turn to their parents for funding. Although insurance companies claim they can withstand further equity falls, many are likely to be forced into strong measures, including capital injections and redemption penalties - or even closing to new business.

Published By Datamonitor
03 Oct 2002
CommentWire
CommentWire

Antisoma/Roche: a powerful alliance

Roche will take over the development of Antisoma's oncology products, including lead drugs Pentumomab and Therex. The deal, which could be worth over $500 million, should benefit both companies. It plugs gaps in Roche's near-term R&D pipeline, while giving Antisoma the benefit of Roche's development and marketing expertise.

Published By Datamonitor
18 Nov 2002
Expert View
Expert View

Asia Pacific booking centers overtake Switzerland

The recent scandals that have engulfed the most prominent Swiss wealth managers, instigating outflows of billions of Swiss francs to other wealth centers, have impacted the role of Switzerland as a top booking center for global HNW individuals. This has contributed to the emergence of Singapore and Hong Kong as among the foremost wealth centers globally in terms of assets held.

Published By Datamonitor
15 Jan 2013
Expert View
Expert View

Asia will pull in wealth as the rest of the world pushes it away

The shift in gravity of the wealth management market will continue its slide east in 2011, with more international clients being serviced from Singapore and Hong Kong. While neither city will rival the US, the UK, or even Switzerland in terms of global client assets under management, 2011 will see the gap narrow as growth in wealth managed from these cities accelerates ahead of the market.

Published By Datamonitor
02 Mar 2011
CommentWire
CommentWire

AstraZeneca: Iressa granted first European approval

Swissmedic has approved the use of Iressa as a third-line treatment for patients with locally advanced and metastatic non-small cell lung cancer. Other European countries are likely to follow suit, making Iressa available throughout Europe. Iressa's commercial potential could be increased if it were used off-label as a second-line treatment or if AstraZeneca [AZN.L] sought other indications.

Published By Datamonitor
08 Mar 2004
Expert View
Expert View

Auf Wiedersehen Wegelin

Wegelin, Switzerland's oldest private bank, has ceased operations and transferred most of its non-US clients and employees to co-operative lender Raiffeisen. The bank was accused by the US Internal Revenue Service of aiding US citizens to avoid millions of dollars in taxes, and is only the latest episode in the agency's global crusade against tax evasion.

Published By Datamonitor
04 Jan 2013
CommentWire
CommentWire

Avalon/Novartis: publicity before the public

Avalon Pharmaceuticals and Novartis have entered into a collaboration to discover small molecule therapeutic compounds using Avalon's AvalonRx drug discovery engine. AvalonRx has been key to past collaborative agreements with large biotech and pharma companies such as MedImmune and Sanofi-Aventis, but with Avalon's imminent public offering of stock, the Novartis deal could be more significant.

Published By Datamonitor
14 Sep 2005
CommentWire
CommentWire

Bank Hofmann: Swiss shift

Bank Hofmann, the independently labeled private bank owned by Credit Suisse [CSR], is stepping up its targeting of wealthy German clients. Bank Hofmann's nascent expansion into the competitive German market sees it attempting to succeed in a challenging area where many other banks have failed.

Published By Datamonitor
12 Oct 2004
Expert View
Expert View

Banking in Switzerland: the end of an era

In the fallout from the financial crisis, Switzerland is coming under increasing pressure to withdraw its banking secrecy laws. In addition to the calls for banking transparency, financial services institutions and governments around the world are fighting to increase their income, a battle which could now threaten Switzerland's dominant position as a wealth management center.

Published By Datamonitor
03 Mar 2009
CommentWire
CommentWire

Barry Callebaut: double chocolate

The Swiss company is moving into consumer chocolate manufacturing by buying Stollwerck, Germany's third largest manufacturer. The country is the second largest market for chocolate in Europe, but competition is hard and only slow market growth is expected. On the plus side, the deal should bring real cost savings

Published By Datamonitor
29 Apr 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.